Sorg Elaine K. 4
4 · Artiva Biotherapeutics, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Artiva (ARTV) Director Elaine Sorg Receives 27,500-Share Award
What Happened
- Elaine K. Sorg, a director of Artiva Biotherapeutics, was granted a derivative equity award of 27,500 shares on February 18, 2026. The award was reported as acquired at $0.00 (no cash paid) — a standard equity grant rather than an open-market purchase or sale.
Key Details
- Transaction type: Award/Grant of derivative shares (code A).
- Date: 2026-02-18; Form 4 filed 2026-02-19 (not indicated as late).
- Price: $0.00 per share; reported total value $0 on the form (reflects grant, not market value).
- Vesting: Per footnote, one-third vested immediately on the grant date; the remaining shares vest monthly over the following two years (i.e., monthly vesting through Feb 2028).
- Shares owned after transaction: Not specified in the provided filing summary.
Context
- This is an equity award (derivative grant) subject to vesting — common for directors and executives as compensation and retention. Such grants are not direct cash purchases and don’t necessarily signal immediate buying or selling intent.
Insider Transaction Report
Form 4
Sorg Elaine K.
Director
Transactions
- Award
Director Stock Option (Right to Buy)
[F1]2026-02-18+27,500→ 27,500 totalExercise: $4.15Exp: 2036-02-17→ Common Stock (27,500 underlying)
Footnotes (1)
- [F1]One-third of the shares vested following the grant date, with the remaining shares vesting monthly over an additional two years following February 18, 2026.
Signature
/s/ Andrew Cronauer, Attorney-in-Fact|2026-02-19